Loading stock data…
TEVA
$34.95-0.12 (-0.34%)
Market ClosedLast close May 1
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Teva Pharmaceutical Industries Limited in the Healthcare sector is trading at $34.95. The stock is currently near its 52-week high of $37.35, remaining 35.0% above its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why TEVA maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$34.95
Potential Downside
31.8%
Whystock Fair Value$23.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$40.09+14.7%
Range$31.00 – $50.00
Fundamentals
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$37.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.80
Beta
Defensive asset. Lower volatility than the S&P 500.
0.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.98%
Volume
Today's trading volume
5.00M
Recent News
Is Deckers Outdoor Corporation (DECK) A Good Stock To Buy Now?
Is DECK a good stock to buy? We came across a bullish thesis on Deckers Outdoor Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on DECK. Deckers Outdoor Corporation’s share was trading at $107.71 as of April 23rd. DECK’s trailing and forward P/E were 15.30 and 14.79 respectively according […]
Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?
Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $31.21 as of April 23rd. TEVA’s trailing and forward P/E were 25.79 and 11.49 […]
Teva (TEVA) Enters a New $700 Million Acquisition Deal
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to acquire Emalex Biosciences. The transaction involves $700 million in cash, plus up to $200 million in milestone payments and royalties. Through the […]
Teva Pharmaceutical Industries Q1 Earnings Call Highlights
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued momentum in its innovative portfolio, while also outlining the company’s first acquisition under its “Pivot to Growth” strategy: the planned purchase of Amylyx and its Tourette syn
Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS Says
Teva Pharmaceutical Industries (TEVA) could see further upside as its valuation re-rates, supported